Event Information:
Date
Tuesday, May 30, 2023
Virtual
Related Models & Services
Xtalks Webinar: How Humanized Mouse Models Enforce Preclinical Studies in Immuno-Oncology
We are excited to invite you to our upcoming free webinar on Tuesday, May 30th at 11 am ET / 4 pm GMT / 5 pm CET, where we will explore the advantages of using Humanized mouse models in immuno-oncology preclinical studies. Our speakers, Dan Georgess, PhD, and Eleonora Leucci, PhD, will provide an overview of drug trials in Humanized mouse models to treat cancer and a novel RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to immune checkpoint blockade.
In the first part of the webinar, Dan Georgess, PhD, Director of Alliance Management at TransCure bioServices, will present an overview of the advantages of using humanized mouse models in immuno-oncology preclinical studies. Humanized mouse models offer several advantages, including the ability to study cancer therapies in vivo, decipher different types of mechanisms of action such as immune checkpoint inhibitors, ADCC, T cell engagers, and cell therapies. Dr. Georgess will also present several case studies demonstrating the advantages of using humanized mouse models for drug trials in immuno-oncology.
In the second part of the webinar, Eleonora Leucci, PhD, Professor at The Laboratory for RNA Cancer Biology, will explore a novel RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to immune checkpoint blockade. The strategy involves using humanized mouse models transplanted with melanoma PDX to study a novel lncRNA LISR-based therapeutic strategy. The study identifies an RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to ICB by downregulating LISR, which leads to strong anti-tumor immune responses in melanoma in vitro, ex vivo, and in vivo, and re-sensitizes to immune checkpoint blockade. Mechanistically, LISR contributes to melanoma immunogenicity by affecting the translation of the checkpoint inhibitor PDL-1 and the assembly of the glycocalyx.
Don’t miss our upcoming free webinar on May 30th to learn more about the advantages of using humanized mouse models in immuno-oncology preclinical studies and a novel RNA-based cancer-specific therapeutic strategy to overcome intrinsic resistance to immune checkpoint blockade.
Register for the live webinar on Tuesday, May 30th, 2023.
Presenting for TransCure bioServices:
Dan Georgess, PhD, Director of Alliance Management
Dan Georgess is an experienced scientist, team leader and project manager. He is dedicated to promoting cross-functional efforts to overcome outstanding challenges in therapeutics development. He joined TransCure as Project Leader and now oversees the Alliance Management Team. Through his Marie Curie Ph.D. training at ENS de Lyon, Suzan G. Komen postdoctoral fellowship at the Johns Hopkins School of Medicine, and his tenure-track leadership of the Cancer Invasion and Metastasis Cluster at the Lebanese American University, Dan has developed cutting-edge ex vivo and in vivo platforms and co-authored 15 peer-reviewed publications.
Presenting for The Art of Discovery:
Eleonora Leucci, PhD, Professor at The Laboratory for RNA Cancer Biology
Eleonora Leucci received her PhD in Medical Biotechnology from the University of Siena in 2007. She then worked as a postdoctoral fellow at BRIC, University of Copenhagen, where she studied non-coding RNAs. Later, she worked as a Marie Curie/VIB postdoctoral fellow in Chris Marine’s lab at VIB, and then as FNRS research associate at ULB, studying the role of lncRNAs in skin cancer. Since 2017, She leads the laboratory for RNA cancer biology and heads the PDX platform TRACE at KU Leuven. In 2018, she was awarded the “Melanoma Research Alliance young investigator award” to study long non-coding RNAs important for therapy resistance.